SCHEMBL17132003

SCHEMBL17132003

CCn1c(-c2ccccc2)cs/c1=N/C(=O)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.71
HSD17B10 Q99714 1/20 0.71
ALDH1A1 P00352 7/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
NPC1 O15118 4/20 0.56
LMNA P02545 3/20 0.56
MAPT P10636 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
GAA P10253 2/20 0.56
MAPK1 P28482 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
RECQL P46063 1/20 0.55
TP53 P04637 3/20 0.53
CA12 O43570 2/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA9 Q16790 2/20 0.52
POLB P06746 1/20 0.51
TSHR P16473 1/20 0.51
KMT2A Q03164 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17107128 1.00 RAB9A (0.71) RAB9AHSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL17107129 1.00 RAB9A (0.71) RAB9AHSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL17132024 0.90 RAB9A (0.61) RAB9AHSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL17107111 0.90 RAB9A (0.61) RAB9AHSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL17107112 0.90 RAB9A (0.61) RAB9AHSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL17133129 0.87 RAB9A (0.62) RAB9AHSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL17107273 0.85 ALOX5 (0.67) RAB9AHSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL17107275 0.85 ALOX5 (0.67) RAB9AHSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL17107239 0.83 RAB9A (0.53) RAB9AHSD17B10ALDH1A1SMN1; SMN2NPC1
SCHEMBL17107101 0.83 RAB9A (0.53) RAB9AHSD17B10ALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210330646-A1 FASCIN BINDING COMPOUNDS FOR SPINOGENESIS SPINOGENIX, INC. 2021-10-28 US disclosed
US-9650369-B2 Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease XAVIER UNIVERSITY OF LOUISIANA (US) 2017-05-16 US disclosed
US-9650369-B2 Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease XAVIER UNIVERSITY OF LOUISIANA (US) 2017-05-16 US disclosed
US-20150274714-A1 ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE XAVIER UNIVERSITY OF LOUISIANA 2015-10-01 US disclosed
US-20150274714-A1 ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE XAVIER UNIVERSITY OF LOUISIANA 2015-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274714-A1 ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE MKI67, MIF, NUDC RAB9A 1305/4885HSD17B10 1947/4885ALDH1A1 1082/4885
US-20210330646-A1 FASCIN BINDING COMPOUNDS FOR SPINOGENESIS FSCN1, SMN1; SMN2, DCX RAB9A 931/4885HSD17B10 2591/4885ALDH1A1 3791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.